Effectiveness and safety of rivaroxaban vs. apixaban in patients with atrial fibrillation and peripheral artery disease

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Cohort study indicates rivaroxaban shows similar risk for MALE and stroke in patients with NVAF and PAD, suggesting apixaban may be safer.

In patients with NVAF and PAD, rivaroxaban showed similar risks for major adverse limb events and stroke compared to apixaban.
Major bleeding rates were significantly higher with rivaroxaban at 46.1 vs. 29.8 per 1000 person-years, indicating safety concerns.
Using propensity score methods, hazard ratios for major adverse events were estimated based on a large cohort of patients during 2013-2021.
These findings highlight the potential for apixaban to be a safer anticoagulant option in high-risk populations with NVAF and PAD.

Dari et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Cohort study indicates rivaroxaban shows similar risk for MALE and stroke in patients with NVAF and PAD, suggesting apixaban may be safer.